EMA says too early to consider fourth COVID-19 dose for general population
Yakobchuk/iStock via Getty Images


Two advisory groups to the European Medicines Agency ("EMA") said there is not evidence to support giving a fourth dose of either the Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) or Moderna (NASDAQ:MRNA) COVID vaccine to the general population.

The EMA COVID-19 task force and the European Centre for Disease Prevention and Control, however, recommended a fourth dose in those 80 years and older due to the higher risk of severe disease in this demographic.
The advisors said there is no evidence that vaccine protection against severe disease is substantially declining in adults with normal immune systems between the ages of 60 and 79.
For those below 60 years old with a normal immune system, "there is currently no conclusive evidence that vaccine protection against severe disease is waning or that there is an added value of a fourth dose."
In late March, the U.S. FDA authorized a second booster (fourth shot) for those aged 50 and older.